search
Back to results

Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells

Primary Purpose

Obesity

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Flexible Sigmoidoscopy
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Obesity focused on measuring Intestinal stem cells

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Subject and Control Inclusion Criteria

  1. Participants have a Body Mass Index (BMI) between 20-25 or 35 and above.
  2. Adults aged 18-65

Exclusion Criteria:

  1. Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory conditions or diabetes mellitus
  2. Antibiotic use within the past 4 weeks (they can be enrolled after a four week washout period and subsequent use during the 6 month study duration does not exclude them)
  3. Bowel preparation for colonoscopy within the past week
  4. Significant bowel surgery other than hysterectomy or appendectomy
  5. Pregnancy or plans to become pregnant within the study time frame
  6. Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
  7. Age<18 or vulnerable adults -

Sites / Locations

  • Mayo Clinic

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Flexible Sigmoidoscopy

Arm Description

Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota

Outcomes

Primary Outcome Measures

Changes in the growth of intestinal stem cells
The gut microbiome is altered in obesity and studying intestinal stem cells will be helpful in learning what triggers intestinal tumors.

Secondary Outcome Measures

Full Information

First Posted
August 3, 2016
Last Updated
February 17, 2022
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT02863029
Brief Title
Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells
Official Title
Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Terminated
Why Stopped
Recruitment difficulty
Study Start Date
January 2017 (Actual)
Primary Completion Date
March 9, 2017 (Actual)
Study Completion Date
March 9, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
New studies are revealing how a high-fat diet could be making the cells of the intestinal lining more likely to become cancerous. The investigators would like to study how obesity influences growth of intestinal stem cells, which could then trigger intestinal tumors. The investigators are proposing a Pilot Study of 20 subjects (comprised of 10 participants from each of two different BMI categories: 20-25 and 35 & above), who will be asked to provide blood, stool, & urine samples, undergo a flexible sigmoidoscopy, and complete food frequency questionnaires
Detailed Description
Hypothesis: The investigators will test the hypothesis that the gut microbiome drives many of the effects that a pro-obesity high-fat diet has on intestinal stem cell (ISC) biology, which includes 1) an increase in ISC numbers and proliferation, 2) a reduced dependency on niche cells for intestinal organoid initiation, or 3) the acquisition of organoid-initiation by non-stem cell population in the intestinal epithelium. Specific Aims: To determine whether differences in the gut microbiome in obese human subjects correlates with enhanced intestinal stem cell numbers and function. To validate whether obesity-driven changes in the gut microbiome of human recapitulate the effects of obesity on intestinal stem cell function in germ-free mice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Intestinal stem cells

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Flexible Sigmoidoscopy
Arm Type
Other
Arm Description
Participants will undergo an unsedated Flexible Sigmoidoscopy in order to obtain 12 mucosal biopsies. Serum cholesterol, triglyceride and HBA1C levels will be determined. Plasma, serum and whole blood will be stored for future use for next generation sequencing and metabolomics to determine the effect of different genetic loci on composition and function of gut microbiota
Intervention Type
Procedure
Intervention Name(s)
Flexible Sigmoidoscopy
Intervention Description
A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
Primary Outcome Measure Information:
Title
Changes in the growth of intestinal stem cells
Description
The gut microbiome is altered in obesity and studying intestinal stem cells will be helpful in learning what triggers intestinal tumors.
Time Frame
Two years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Subject and Control Inclusion Criteria Participants have a Body Mass Index (BMI) between 20-25 or 35 and above. Adults aged 18-65 Exclusion Criteria: Known diagnosis of inflammatory bowel disease, microscopic colitis, celiac disease or other inflammatory conditions or diabetes mellitus Antibiotic use within the past 4 weeks (they can be enrolled after a four week washout period and subsequent use during the 6 month study duration does not exclude them) Bowel preparation for colonoscopy within the past week Significant bowel surgery other than hysterectomy or appendectomy Pregnancy or plans to become pregnant within the study time frame Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes. Age<18 or vulnerable adults -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Purna C Kashyap, M.
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Tissue samples will be sent to the Massachusetts Institute of Technology (MIT)
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells

We'll reach out to this number within 24 hrs